Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.77 |
| ▸ | PPARD | Q03181 | 2/20 | 0.77 |
| ▸ | PPARA | Q07869 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | CYSLTR2 | Q9NS75 | 15/20 | 0.74 |
| ▸ | CYSLTR1 | Q9Y271 | 15/20 | 0.74 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3894010 | 0.89 | PPARG (0.80) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL9301519 | 0.88 | CYSLTR2 (0.86) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL6244980 | 0.87 | GRM2 (0.76) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL2067483 | 0.87 | PPARG (1.00) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL29369990 | 0.87 | PPARG (1.00) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL9301387 | 0.86 | CYSLTR2 (0.85) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL9733661 | 0.86 | GRM2 (0.75) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL10690991 | 0.85 | CYSLTR2 (0.87) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL10693685 | 0.85 | CYSLTR2 (0.87) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL9302516 | 0.85 | CYSLTR2 (0.87) | PPARGPPARDPPARALMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239854-A1 | Body weight gain inhibitors | SUGIYAMA YASUO | 2005-10-27 | — | — | US | disclosed |
| EP-1304121-A1 | BODY WEIGHT GAIN INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239854-A1 | Body weight gain inhibitors | PPARG, GPR119, PPARA | PPARG 1/4885PPARD 5/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.